Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola
Psychedelic Alpha’s Josh Hardman speaks with newly appointed Helus Pharma CEO Michael Cola in a brief Q&A on execution, regulatory rigor, and scaling serotonergic CNS medicines.
External link. We are not responsible for the content.
Read more ↗More From Psychedelic Alpha
Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published
Policy Round-Up: State Momentum, Congressional Signals, and Colorado’s Data Build-Out • RAND Survey: Americans Divi...
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
AtaiBeckley is in structured discussions with pharma companies and royalty investors about a potential partnership fo...
Pα+ February 2026 Psychedelic Bill Roundup
A state-by-state and federal review of psychedelics-related bills introduced or advanced in February 2026, including ...
Latest News
Where Does the World Go to Dance? Probs These EDM Festivals
A global guide to the festivals worth planning for. [...] Read More... The post Where Does the World Go to Dance? Pro...
Inclius Alvarious’s Place Within Indigenous Society
A look at Sonoran Desert toad medicine through the lens of indigenous sovereignty, ecological strain, and the debate ...
Can you kill a bad trip?: 5 Questions for emergency physician Gregory Yates
Yates discusses experimental attempts to end a psychedelic trip early.
Psychedelic Faeries Take on Prohibition and Authoritarianism
Plus psychedelics and telepathy, ego death for the rich, and our brain on Chat GPT [...] Read More... The post Psyche...
Introduction to Trip Sitting
The Art and Science of Holding Psychedelic Space
Heartbreak is a Bad Trip
Oli Genn-Bash describes how the aftermath of a sudden breakup felt like a prolonged ‘bad trip’, as well as the potent...